Backed by a multi-hundred-million-dollar investment, the expansion underscores Sanofi’s long-term commitment to India’s thriving life sciences ecosystem
BioAsia 2026 represents a decisive shift toward execution, scale, and global competitiveness, reflecting the rapid evolution of the life sciences ecosystem
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
The successive PLI disbursements validate our disciplined execution and sustained commitment to strengthening India’s domestic pharmaceutical manufacturing capabilities
India should explore Sustainability-Linked Incentives (SLI) targeting innovations in the 12 principles of green chemistry
India’s pharmaceutical sector stands at a pivotal inflection point
The new single-use commercial facility will be among India’s largest, featuring advanced technologies to produce high-quality biologics and specialty pharmaceuticals
Ascelis Center of Excellence for Peptide Development and Characterization will drive the development of cosmetic, therapeutic, and pharmaceutical peptides
The quarter included three IPOs worth US$ 428 million and one Qualified Institutional Placement (QIP) worth US$ 88 million
Launches National IVD validation portal and protocols; highlights India’s strengthening health research ecosystem
Subscribe To Our Newsletter & Stay Updated
